Generation of Engineered Pluripotent Cell-Derived NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy

6/19/2018
10:15 - 10:40

Bob Valamehr

Fate Therapeutics, Inc, United States

Bob Valamehr is the Vice President of Cancer Immunotherapy at Fate Therapeutics, overseeing the company’s immuno-oncology and pluripotent stem cell programs, including efforts to develop novel pluripotent cell strategies to create “off-the-shelf” cell-based cancer immunotherapeutics. Previously, Dr. Valamehr has played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA and his M.B.A. from Pepperdine University.

Presentation(s):

Send Email for Bob Valamehr


Assets

Generation of Engineered Pluripotent Cell-Derived NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Generation of Engineered Pluripotent Cell-Derived NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy